News
I remain bearish on Pfizer due to pricing pressures from IRA/340B and a looming 2026 patent cliff, despite Q2 2025 earnings beat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback